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Abstract
Aims: We sought to assess the performance of drug-eluting stents combining an ultrathin cobalt-chromium 
platform with a biodegradable polymer across categories of increasing SYNTAX score (SS).
Methods and results: Patients included in the BIOSCIENCE trial and randomly allocated to treatment 
with biodegradable polymer sirolimus-eluting stents (BP-SES) or durable polymer everolimus-eluting 
stents (DP-EES) were categorised according to SS tertiles (low <8, medium 8-15, high >15). The primary 
endpoint, target lesion failure (TLF), was defined as a composite of cardiac death, target vessel myocardial 
infarction and clinically indicated target lesion revascularisation. The patient-oriented endpoint (POCE) 
included death, myocardial infarction, or any repeat revascularisation. The SS was available in 2,041 out 
of 2,119 patients (96.3%). At two-year follow-up, patients with an SS >15 experienced higher rates of both 
TLF and POCE as compared to patients with medium and low SS (14.5% vs. 8.1% and vs. 5.9%, p<0.001; 
22.7% vs. 14.9% and vs. 12.4%; p<0.001), respectively. Comparable rates of the composite endpoints were 
documented for both stent types in each category of SS.
Conclusions: Increasing lesion complexity as assessed by SS was associated with higher rates of TLF and 
POCE in a contemporary PCI population with minimal exclusion criteria. BP-SES and DP-EES showed 
comparable performance across the entire spectrum of CAD severity.
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Introduction
Originally conceived as a scoring system for angiographic extent 
and complexity of coronary artery disease (CAD)1, the SYNTAX 
score (SS) has been correlated with the risk of adverse events after 
percutaneous coronary intervention (PCI) in patients receiving 
early- and new-generation drug-eluting stents (DES)2-4.
Refinements of the platform and the design of DES facilitated 
the treatment of increasingly complex CAD. Improved deliverabil-
ity achieved by a reduction of strut thickness was paralleled by 
a decline of ischaemic events using biocompatible und biodegrad-
able polymers5.
The randomised BIOSCIENCE trial (NCT01443104) showed 
the non-inferiority of the Orsiro stent (Biotronik AG, Bülach, 
Switzerland), featuring an ultrathin strut cobalt-chromium design 
in combination with a biodegradable sirolimus-eluting polymer 
(BP-SES), compared to the durable polymer everolimus-eluting 
stent (DP-EES) (XIENCE PRIME®/Xpedition®; Abbott Vascular, 
Santa Clara, CA, USA) with regard to a composite clinical out-
come among patients with minimal exclusion criteria6.
The effect of an ultrathin strut stent design in combination with 
a biodegradable polymer on clinical outcome according to SS is 
unknown.
In the present substudy of the BIOSCIENCE trial, we sought to 
explore whether the predictability of the SS is confirmed in a con-
temporary PCI population and whether the complexity of CAD, as 
assessed by SS, differentially affects clinical outcomes up to two 
years after PCI with BP-SES or DP-EES. Furthermore, we evalu-
ated the performance of the logistic clinical SS, which combines 
anatomical SS with clinical features7, to predict survival in a con-
temporary PCI population.
Methods
STUDY POPULATION AND PROCEDURES
The BIOSCIENCE trial was an investigator-initiated, multicen-
tre, single-blind, randomised non-inferiority trial including patients 
with stable CAD and acute coronary syndromes (ACS) who were 
candidates for stenting. The trial design and criteria for inclusion 
and exclusion have previously been described8. The study complied 
with the Declaration of Helsinki. Written informed consent was 
mandatory for study inclusion. The study protocol was approved 
by the ethics committees of all participating centres. After diag-
nostic angiography, patients were randomly allocated (1:1) to treat-
ment with BP-SES or DP-EES using a web-based system. All 
patients were clinically followed up at 30 days, 12 and 24 months.
STUDY ENDPOINTS
The primary endpoint of this sub-analysis was the occurrence 
of target lesion failure (TLF), defined as a composite of cardiac 
death, target vessel Q-wave or non-Q-wave myocardial infarction 
(MI) and clinically indicated target lesion revascularisation (TLR). 
Secondary endpoints were a patient-oriented composite endpoint 
(POCE), including death, MI, or any repeat revascularisation, the 
individual components of the composite primary endpoint, and 
Academic Research Consortium (ARC)-defined stent thrombosis 
(ST). Endpoint definitions have been provided elsewhere6.
Calculation of SS, logistic clinical SS and statistical analysis are 
described in the Appendix.
Results
The SS was available in 2,041 out of 2,119 patients enrolled into 
the BIOSCIENCE trial (96.3%), and ranged from 0 to 63.5 with 
a mean±SD of 14±11.4 and a median of 11.0 (interquartile range 6 
to 18). Patients randomly allocated to either one of the two treat-
ment arms were categorised according to SS tertiles: low SS: <8 
(BP-SES, n=346 and DP-EES, n=355), medium SS: 8-15 (BP-SES, 
n=317 and DP-EES, n=342), and high SS: >15 (BP-SES, n=346 
and DP-EES, n=334).
BASELINE CLINICAL FEATURES
Baseline parameters were well balanced between the two treat-
ment arms across SS tertiles, except for a significantly higher 
number of previous cerebrovascular events among patients with 
medium SS in the DP-EES arm as compared to the BP-SES arm 
(7.3% vs. 3.5%, p=0.04) (Table 1). Angiographic features and pro-
cedural data are reported in Table 2.
CLINICAL OUTCOMES ACCORDING TO CAD COMPLEXITY
Figure 1 shows cumulative survival curves for the primary end-
point TLF (Figure 1A) and the composite POCE (Figure 1B) in the 
overall population stratified according to SS tertile. Patients with 
SS >15 experienced significantly higher rates of adverse events 
as compared to patients in the lower SS categories. Rates of TLF 
were 14.5%, 8.1% and 5.9% in high, medium and low SS groups, 
respectively (p<0.001). Similarly, POCE occurred in 22.7% of high 
SS patients, 14.9% of medium SS patients, and 12.4% of low SS 
patients (p<0.001). These differences were driven by higher rates 
of cardiac death (high SS 5.3%, medium SS 2.2%, low SS 1.6%, 
p<0.001), target vessel MI (high SS 5.7%, medium SS 3.6%, low 
SS 2.1%, p=0.001) and clinically indicated TLR (high SS 7.4%, 
medium SS 3.6%, low SS 3.5%, p=0.001). Moreover, the occur-
rence of definite or probable ST was more frequent among high 
SS patients (5.9% compared with 3.4% and 2.2% in medium and 
low SS patients, respectively, p<0.001) (Table 3).
CLINICAL OUTCOMES ACCORDING TO STENT TYPE ACROSS 
SS TERTILES
Table 4 and Figure 2 display clinical outcomes at two years strati-
fied by stent type and SS tertile. Rates of TLF were not signifi-
cantly different between treatment arms across SS tertiles: high SS, 
BP-SES 13.9% vs. DP-EES 15.1%, RR 0.91 (95% CI [0.61-1.37]), 
p=0.66; medium SS, BP-SES 6.6% vs. DP-EES 9.5%, RR 0.64 
(95% CI [0.36-1.13]), p=0.12; low SS, BP-SES 5.7% vs. DP-EES 
6.1%, RR 0.94 (95% CI [0.51-1.76]), p=0.85. Similarly, no signif-
icant differences were detected in the occurrence of POCE: high 
SS, BP-SES 23% vs. DP-EES 22.4%, RR 1.03 (95% CI [0.75-
1.41]), p=0.87; medium SS, BP-SES 14.4% vs. DP-EES 15.4%, 
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SYNTAX score in BIOSCIENCE trial
Table 1. Baseline clinical characteristics of study population.
 
 
 
Low SS 
p-value
Medium SS
p-value
High SS
p-valueBP-SES DP-EES BP-SES DP-EES BP-SES DP-EES
n=346 n=355 n=317 n=342 n=346 n=334
Age, years 64.2±12.1 63.5±11.0 0.45 65.0±11.6 65.6±11.4 0.50 69.0±10.5 68.6±10.9 0.71
Male gender 262 (75.7%) 272 (76.6%) 0.79 252 (79.5%) 255 (74.6%) 0.14 262 (75.7%) 267 (79.9%) 0.20
Body mass index, kg/m2 27.7±4.6 27.6±4.8 0.74 27.8±4.4 27.7±4.6 0.81 27.8±4.5 27.4±4.1 0.25
Hypertension 231 (66.8%) 215 (60.7%) 0.10 214 (67.7%) 236 (69.0%) 0.74 245 (70.8%) 234 (70.1%) 0.87
Hypercholesterolaemia 222 (64.2%) 239 (67.3%) 0.38 210 (66.5%) 220 (64.3%) 0.62 242 (69.9%) 239 (71.6%) 0.67
Current smoker 123 (35.5%) 121 (34.1%) 0.69 98 (31.0%) 95 (27.8%) 0.39 77 (22.3%) 79 (23.8%) 0.65
Family history of CAD 90 (26.2%) 87 (24.6%) 0.66 89 (28.2%) 104 (30.4%) 0.55 96 (27.9%) 96 (28.7%) 0.87
Previous MI 59 (17.1%) 58 (16.3%) 0.84 63 (19.9%) 60 (17.5%) 0.48 86 (24.9%) 82 (24.6%) 0.93
Previous PCI 92 (26.6%) 81 (22.8%) 0.26 95 (30.0%) 91 (26.6%) 0.34 118 (34.1%) 110 (32.9%) 0.81
Previous CABG 2 (0.6%) 4 (1.1%) 0.69 4 (1.3%) 7 (2.0%) 0.55 95 (27.5%) 83 (24.9%) 0.49
Atrial fibrillation/atrial flutter 23 (6.6%) 24 (6.8%) 1.00 22 (6.9%) 25 (7.3%) 0.88 34 (9.8%) 29 (8.7%) 0.69
Previous stroke or TIA 8 (2.3%) 13 (3.7%) 0.38 11 (3.5%) 25 (7.3%) 0.04 19 (5.5%) 15 (4.5%) 0.60
Peripheral vascular disease 20 (5.8%) 25 (7.0%) 0.54 33 (10.4%) 26 (7.6%) 0.22 36 (10.4%) 25 (7.5%) 0.23
Renal failure (GFR <60 ml/min)  36 (11.2%) 29 (8.6%) 0.30 39 (12.8%) 44 (13.6%) 0.81 59 (17.9%)  55 (17.7%) 1.00
Unstable angina 24 (6.9%) 21 (5.9%) 0.65 26 (8.2%) 29 (8.5%) 1.00 23 (6.6%) 21 (6.3%) 0.88
NSTEMI 87 (25.1%) 100 (28.2%) 0.39 92 (29.0%) 97 (28.4%) 0.86 100 (28.9%) 83 (24.9%) 0.26
STEMI 79 (22.8%) 70 (19.7%) 0.36 65 (20.5%) 61 (17.8%) 0.43 60 (17.3%) 62 (18.6%) 0.69
Stable angina 120 (34.7%) 126 (35.5%) 0.87 100 (31.5%) 123 (36.0%) 0.25 129 (37.3%) 134 (40.1%) 0.48
Silent ischaemia 36 (10.4%) 38 (10.7%) 0.90 34 (10.7%) 32 (9.4%) 0.60 34 (9.8%) 34 (10.2%) 0.90
 Acute MI within 72 hrs 59 (17.1%) 54 (15.2%) 0.54 50 (15.8%) 47 (13.7%) 0.51 51 (14.7%) 48 (14.4%) 0.91
Left ventricular ejection fraction n=277 n=287 0.29 n=256 n=267 0.64 n=290 n=277 0.79
≤30% 7 (2.5%) 13 (4.5%) 0.26 14 (5.5%) 12 (4.5%) 0.69 17 (5.9%) 16 (5.8%) 1.00
31%-50% 66 (23.8%) 58 (20.2%) 0.31 86 (33.6%) 82 (30.7%) 0.51 106 (36.6%) 109 (39.4%) 0.55
>50% 204 (73.6%) 216 (75.3%) 0.70 156 (60.9%) 173 (64.8%) 0.37 167 (57.6%) 152 (54.9%) 0.55
Multivessel treatment 24 (7.0%) 28 (7.9%) 0.67 77 (24.3%) 78 (22.8%) 0.71 93 (26.9%) 100 (29.9%) 0.40
Data expressed as n (%) or mean±standard deviation. P-values from Fisher’s tests or chi-square tests (more than two categories) or unpaired t-tests, respectively. 
BP-SES: biodegradable polymer sirolimus-eluting stent; CABG: coronary artery bypass graft; CAD: coronary artery disease; DP-EES: durable polymer everolimus-
eluting stent; MI: myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment 
elevation myocardial infarction; TIA: transient ischaemic attack
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Figure 1. Kaplan-Meier estimates up to two years of follow-up. A) Target lesion failure (TLF). B) Patient-oriented composite endpoint 
(POCE). Grey lines indicate low SS (<8), orange lines indicate medium SS (8-15), red lines indicate high SS (>15).
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Table 2. Baseline lesion characteristics stratified by SYNTAX tertile and treatment arm.
Low SYNTAX score
p-value
Medium SYNTAX score
p-value
High SYNTAX score
p-valueBP-SES DP-EES BP-SES DP-EES BP-SES DP-EES
No. of patients n=346 n=355 n=317 n=342 n=346 n=334
No. of lesions 413 423 507 508 606 579
Target vessel location per lesion ‡ n=413 n=423 0.51 n=507 n=508 0.49 n=606 n=579 0.12
Left main artery 0 (0.0%) 0 (0.0%) 3 (0.6%) 2 (0.4%) 23 (3.8%) 24 (4.1%)
Left anterior descending artery 129 (31.2%) 132 (31.2%) 251 (49.5%) 269 (53.0%) 244 (40.3%) 271 (46.8%)
Left circumflex artery 109 (26.4%) 125 (29.6%) 110 (21.7%) 92 (18.1%) 136 (22.4%) 111 (19.2%)
Right coronary artery 175 (42.4%) 166 (39.2%) 143 (28.2%) 145 (28.5%) 170 (28.1%) 131 (22.6%)
Bypass graft Saphenous vein graft 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 30 (5.0%) 37 (6.4%)
Arterial graft 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.5%) 5 (0.9%)
No. of treated lesions per patient ¶ 1.19±0.46 1.19±0.48 0.98 1.60±0.78 1.49±0.68 0.24 1.75±0.95 1.73±0.88 0.86
No. of treated lesions per patient ‡ n=346 n=355 0.98 n=317 n=342 0.24 n=346 n=334 0.86
One 287 (82.9%) 299 (84.2%) 173 (54.6%) 208 (60.8%) 178 (51.4%) 164 (49.1%)
Two 52 (15.0%) 45 (12.7% ) 108 (34.1%) 107 (31.3%) 100 (28.9%) 109 (32.6%)
Three 6 (1.7%) 10 (2.8%) 28 (8.8%) 22 (6.4%) 49 (14.2%) 52 (15.6%)
≥Four 1 (0.3%) 1 (0.3%) 8 (2.5%) 5 (1.5%) 19 (5.5%) 9 (2.7%)
Type of intervention per lesion* n=413 n=423 0.36 n=507 n=508 0.18 n=606 n=579 0.94
Stenting 399 (96.6%) 413 (97.6%) 479 (94.5%) 489 (96.3%) 573 (94.6%) 547 (94.5%)
Ballooning 9 (2.2%) 10 (2.4%) 27 (5.3%) 18 (3.5%) 32 (5.3%) 31 (5.4%)
CABG 2 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%)
Failed PCI 3 (0.7%) 0 (0.0%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 0 (0.0%)
Baseline TIMI flow per lesion n=398 n=414 0.76 n=497 n=501 0.97 n=601 n=573 0.28
0 or 1 92 (23.1%) 98 (23.7%) 85 (17.1%) 83 (16.6%) 129 (21.5%) 106 (18.5%)
2 46 (11.6%) 41 (9.9%) 70 (14.1%) 72 (14.4%) 99 (16.5%) 111 (19.4%)
3 260 (65.3%) 275 (66.4%) 342 (68.8%) 346 (69.1%) 373 (62.1%) 356 (62.1%)
TIMI flow post PCI per lesion n=404 n=421 0.61 n=504 n=506 0.34 n=601 n=578 0.94
0 or 1 1 (0.2%) 1 (0.2%) 0 (0.0%) 2 (0.4%) 3 (0.5%) 3 (0.5%)
2 3 (0.7%) 1 (0.2%) 5 (1.0%) 1 (0.2%) 12 (2.0%) 10 (1.7%)
3 400 (99.0%) 419 (99.5%) 499 (99.0%) 503 (99.4%) 586 (97.5%) 565 (97.8%)
Restenotic lesion per lesion 30 (7.3%) 20 (4.7%) 0.13 29 (5.7%) 22 (4.3%) 0.32 44 (7.3%) 29 (5.0%) 0.09
Total occlusion per lesion 93 (22.6%) 88 (20.9%) 0.51 87 (17.2%) 74 (14.7%) 0.28 90 (14.9%) 86 (14.9%) 1.00
Thrombus aspiration per lesion 62 (15.1%) 48 (11.4%) 0.10 41 (8.1%) 40 (7.9%) 0.86 37 (6.1%) 37 (6.4%) 0.84
Number of stents per lesion 1.18±0.45 1.23±0.52 0.50 1.32±0.62 1.34±0.64 0.81 1.38±0.68 1.41±0.70 0.63
Total stent length per lesion (mm) 22.00±11.06 23.18±11.55 0.13 26.06±14.94 27.42±16.70 0.18 28.80±17.99 30.82±19.23 0.10
Maximum stent diameter per lesion (mm) 3.04±0.50 3.01±0.52 0.33 3.06±0.48 3.05±0.47 0.91 3.04±0.48 3.02±0.49 0.47
Maximum pressure per lesion (atm) 13.76±3.46 13.32±3.15 0.06 13.54±3.56 13.79±3.32 0.50 13.94±3.49 14.03±3.50 0.55
Overlapping stents per lesion 56 (14.0%) 71 (17.2%) 0.22 103 (21.5%) 120 (24.5%) 0.26 140 (24.4%) 150 (27.4%) 0.27
Direct stenting per lesion 130 (32.6%) 136 (32.9%) 0.79 141 (29.4%) 154 (31.5%) 0.48 131 (22.9%) 139 (25.4%) 0.29
Long lesion per lesion (>20 mm) 164 (41.1%) 194 (47.0%) 0.10 273 (57.0%) 282 (57.7%) 0.83 355 (62.0%) 348 (63.6%) 0.66
Small vessel per lesion (<2.75 mm) 149 (37.3%) 186 (45.0%) 0.02 189 (39.5%) 204 (41.7%) 0.44 259 (45.2%) 267 (48.8%) 0.26
Bifurcation treatment per lesion 36 (8.8%) 28 (6.6%) 0.69 95 (18.8%) 99 (19.5%) 0.75 121 (20.0%) 123 (21.3%) 0.76
Type of stent per lesion 0.16 0.49 0.44
Study stent BP-SES 393 (98.5%) 1 (0.2%) 472 (98.5%) 3 (0.6%) 571 (99.7%) 5 (0.9%)
Study stent DP-EES 3 (0.8%) 412 (99.8%) 7 (1.5%) 485 (99.2%) 2 (0.3%) 543 (99.3%)
Other drug-eluting stent 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%)
Bare metal stent 3 (0.8%) 1 (0.2%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%)
IABP per patient 1 (0.3%) 1 (0.3%) 0.99 1 (0.3%) 0 (0.0%) 0.48 1 (0.3%) 1 (0.3%) 1.00
Vasopressors per patient 3 (0.9%) 1 (0.3%) 0.33 0 (0.0%) 1 (0.3%) 1.00 6 (1.7%) 0 (0.0%) 0.03
Data expressed as n (%) or mean±standard deviation. P-values from ¶Poisson regression and ‡chi-square tests or Fisher’s test; otherwise p-values from mixed models for the 
per-lesion analyses, accounting for lesions nested within patients: general linear mixed models for continuous variables, generalised linear mixed models for counts no. *p-value 
for stenting vs. non-stenting per patient. Long lesion: total stent length >20 mm; Small vessel: minimum stent diameter <2.75 mm. BP-SES: biodegradable polymer sirolimus-
eluting stent; CABG: coronary artery bypass graft; DP-EES: durable polymer everolimus-eluting stent; IABP: intra-aortic balloon pump; PCI: percutaneous coronary intervention
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SYNTAX score in BIOSCIENCE trial
RR 0.89 (95% CI [0.60-1.34]), p=0.58; low SS, BP-SES 13% vs. 
DP-EES 11.9%, RR 1.12 (95% CI [0.73-1.71]) p=0.62. However, 
among patients in the medium SS tertile, there was an increase 
in the rates of target vessel MI and definite or probable ST with 
DP-EES as compared to BP-SES (target vessel MI, BP-SES: 1.6% 
vs. DP-EES 5.3%, RR 0.30 (95% CI [0.11-0.81]), p=0.01; defi-
nite or probable ST, BP-SES: 1.6% vs. DP-EES 5.0%, RR 0.31 
(95% CI [0.12-0.86]), p=0.02). The interaction p-value between 
Table 3. Clinical outcomes according to CAD complexity.
SYNTAX score
p-value interaction p-value¶Low (<8)
n=701
Medium (8-15)
n=659
High (>15)
n=680
Target lesion failure 0verall 40 (5.9) 51 (8.1) 96 (14.5) <0.001 <0.001 
 
 
0-1 year 22 (3.2) 33 (5.1) 67 (10.0) <0.001
1 year-2 years 18 (2.8) 18 (3.2) 29 (5.1) 0.048
Cardiac death 0verall 11 (1.6) 14 (2.2) 35 (5.3) <0.001 <0.001
 
 
0-1 year 6 (0.9) 9 (1.4) 25 (3.7) <0.001
1 year-2 years 5 (0.8) 5 (0.8) 10 (1.6) 0.146
TV myocardial infarction (any) 0verall 14 (2.1) 23 (3.6) 37 (5.7) 0.001 0.002
 
 
0-1 year 8 (1.2) 18 (2.8) 26 (3.9) 0.002
1 year-2 years 6 (0.9) 5 (0.8) 11 (1.9) 0.146
Clinically indicated TLR 0verall 23 (3.5) 22 (3.6) 47 (7.4) 0.001 0.001
 
 
0-1 year 10 (1.5) 9 (1.4) 28 (4.2) 0.001
1 year-2 years 13 (2.0) 13 (2.3) 19 (3.3) 0.190
POCE 0verall 85 (12.4) 95 (14.9) 151 (22.7) <0.001 <0.001
 
 
0-1 year 49 (7.1) 53 (8.1) 98 (14.5) <0.001
1 year-2 years 36 (5.8) 42 (7.3) 53 (9.6) 0.016
Definite stent thrombosis 0verall 3 (0.5) 4 (0.6) 8 (1.2) 0.100 0.229‡
 
 
0-1 year 0 (0.0) 2 (0.3) 7 (1.1) 0.013
1 year-2 years 3 (0.5) 2 (0.3) 1 (0.2) 0.646
Definite or probable stent 
thrombosis
0verall 15 (2.2) 22 (3.4) 39 (5.9) <0.001 0.001
 
 
0-1 year 9 (1.3) 18 (2.8) 28 (4.2) 0.001
1 year-2 years 6 (0.9) 4 (0.7) 11 (1.9) 0.143
Number of first events and percentages are reported. Mantel-Cox regression with two-sided p-values from a log-rank test. ¶Approximate chi-square test 
for effect modification of the overall difference between SYNTAX tertiles due to the period (0-30 days vs. 31-365 days). ‡Approximate Z-test for risk 
modification comparing the two follow-up periods. POCE: patient-oriented composite endpoint; TLR: target lesion revascularisation; TV: target vessel
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Figure 2. Kaplan-Meier estimates according to stent type up to two years of follow-up. A) Target lesion failure (TLF). B) Patient-oriented 
composite endpoint (POCE). Grey lines indicate low SS (<8), orange lines indicate medium SS (8-15), red lines indicate high SS (>15). 
BP-SES=solid lines; DP-EES=dashed lines.
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treatment arms and SS tertiles for these endpoints was 0.045 and 
0.27, respectively, meriting caution when interpreting the final 
results. Furthermore, in the high SS tertile, the rate of cardiac 
death was significantly higher in patients receiving DP-EES as 
compared to BP-SES (7.0% vs. 3.6%, RR 0.50 [95% CI (0.25-
1.00)], p=0.04). One-year outcomes according to stent type and 
stratified by SS tertile are reported in Table 5.
PERFORMANCE OF THE LOGISTIC CLINICAL SYNTAX SCORE
Figure 3 shows Kaplan-Meier mortality curves for tertiles of logis-
tic clinical SYNTAX score (low: 0-5; medium: 6-10; high: 11-22). 
Increasing categories of scores were associated with higher risk 
of death at two-year follow-up: high vs. low, RR 7.21 (95% CI 
[3.78-13.75]), p<0.001; medium vs. low, RR 2.15 (95% CI [1.07-
4.30]), p=0.03. As displayed in Figure 4A and Figure 4B, the score 
showed fair discrimination (Harrell’s c-index 0.73, 95% CI: 0.68-
0.78) and good calibration.
Discussion
The main findings of the present study are the following:
1. The predictive value of the SS is confirmed among patients 
undergoing PCI with new-generation DES.
2. BP-SES and DP-EES perform similarly across the entire spec-
trum of CAD complexity throughout two years of follow-up 
Table 4. Two-year clinical outcomes according to stent type across tertiles of SS.
 
 
BP-SES
n=1,009
DP-EES
n=1,031
Risk difference 
(95% CI) 
Risk ratio 
(95% CI) 
p-value  interaction
 p-value¶
Target lesion failure High SYNTAX score 47 (13.9) 49 (15.1) –1.09 (–6.32 to 4.15) 0.91 (0.61-1.37) 0.66 0.55
 
 
Medium SYNTAX score 19 (6.6) 32 (9.5) –3.36 (–7.41 to 0.68) 0.64 (0.36-1.13) 0.12
Low SYNTAX score 19 (5.7) 21 (6.1) –0.42 (–3.86 to 3.01) 0.94 (0.51-1.76) 0.85
Cardiac death High SYNTAX score 12 (3.6) 23 (7.0) –3.42 (–6.75 to –0.09) 0.50 (0.25-1.00) 0.04 0.040
 
 
Medium SYNTAX score 9 (3.0) 5 (1.5) 1.38 (–0.85 to 3.60) 2.01 (0.68-5.99) 0.20
Low SYNTAX score 7 (2.1) 4 (1.2) 0.90 (–0.95 to 2.74) 1.83 (0.53-6.27) 0.33
Target vessel MI (any) High SYNTAX score 21 (6.3) 16 (5.0) 1.28 (–2.12 to 4.68) 1.25 (0.65-2.41) 0.50 0.045
 
 
Medium SYNTAX score 5 (1.6) 18 (5.3) –3.69 (–6.42 to –0.95) 0.30 (0.11-0.81) 0.01
Low SYNTAX score 5 (1.5) 9 (2.6) –1.0 (–3.15 to 0.97) 0.58 (0.19-1.72) 0.32
Clinically indicated TLR High SYNTAX score 29 (8.7) 18 (6.0) 2.99 (–0.80 to 6.79) 1.56 (0.87-2.81) 0.14 0.10
 
 
Medium SYNTAX score 7 (2.7) 15 (4.5) –2.18 (–4.88 to 0.53) 0.52 (0.21-1.26) 0.14
Low SYNTAX score 10 (3.1) 13 (3.8) –0.77 (–3.40 to 1.86) 0.81 (0.35-1.84) 0.61
POCE High SYNTAX score 78 (23.0) 73 (22.4) 0.69 (–5.56 to 6.93) 1.03 (0.75-1.41) 0.87 0.75
 
 
Medium SYNTAX score 43 (14.4) 52 (15.4) –1.64 (–7.00 to 3.72) 0.89 (0.60-1.34) 0.58
Low SYNTAX score 44 (13.0) 41 (11.9) 1.17 (–3.67 to 6.00) 1.12 (0.73-1.71) 0.62
Definite stent 
thrombosis
High SYNTAX score 5 (1.5) 3 (0.9) 0.55 (–1.07 to 2.16) 1.60 (0.38-6.71) 0.52 0.48
 
 
Medium SYNTAX score 1 (0.3) 3 (0.9) –0.56 (–1.73 to 0.60) 0.37 (0.04-3.57) 0.37
Low SYNTAX score 1 (0.3) 2 (0.6) –0.27 (–1.24 to 0.69) 0.53 (0.05-5.84) 0.60
Definite or probable 
stent thrombosis
High SYNTAX score 18 (5.4) 21 (6.5) –1.09 (–4.59 to 2.42) 0.81 (0.43-1.53) 0.52
0.27
 Medium SYNTAX score 5 (1.6) 17 (5.0) –3.39 (–6.07 to –0.71) 0.31 (0.12-0.86) 0.02
Low SYNTAX score 6 (1.8) 9 (2.6) –0.80 (–2.94 to 1.34) 0.69 (0.24-1.95) 0.48
Number of first events and percentages are reported. Rate ratios (RR [95% CI]) are estimated using the Mantel-Cox method with two-sided p-values 
from log-rank test. ¶Approximate chi-square test for unequal RRs testing for effect modification of the difference between the stents due to the tertile 
groups. Approximate Z-test in case of zero events. MI: myocardial infarction; POCE: patient-oriented composite endpoint; TLR: target lesion 
revascularisation
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High vs. low RR (95% CI)=7.21 (3.78-13.75)
p<0.001
Medium vs. low RR (95% CI)=2.15 (1.07-4.30)
p=0.031
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Days since index procedureNumber at risk
Low 0-5 687 672 671 671 670 668 666 648 646 645 645 645 644
Medium 6-10 834 826 824 820 819 814 812 801 800 797 793 791 784
High 11-22 519 497 492 488 486 478 468 459 455 453 453 451 441
Figure 3. Kaplan-Meier estimates of all-cause death at two years of 
follow-up for low, medium and high tertiles of logistic clinical SS. 
Grey line indicates low logistic clinical SS (0-5), orange line 
indicates medium logistic clinical SS (6-10), red line indicates high 
logistic clinical SS (11-22).
with regard to a lesion-oriented and a patient-oriented compos-
ite endpoint. Differences in individual endpoints across SS cat-
egories need to be evaluated in larger studies.
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SYNTAX score in BIOSCIENCE trial
After its introduction as an angiographic instrument to grade 
the extent and severity of CAD1, the SS proved to be an effec-
tive predictor of clinical outcomes in several settings. Specifically, 
the paradigm relating high anatomic complexity (higher SS) with 
higher rates of adverse ischaemic events has been validated in 
patients undergoing PCI with early- and newer-generation DES9-11. 
In an ad hoc analysis of the RESOLUTE All Comers trial, the 
SS was identified as an independent predictor of adverse ischae-
mic events, with patients in the highest SS tertile experiencing 
higher rates of POCE, TLF, MI, repeat revascularisation and ST3. 
Table 5. One-year clinical outcomes according to stent type across tertiles of SS.
BP-SES
n=1,010
DP-EES
n=1,031
Risk difference
(95% CI)
Risk ratio
(95% CI)
p-value interactionp-value¶
Target lesion 
failure**
High SYNTAX score 31 (9.1) 35 (10.6) –1.52 (–5.97 to 2.94) 0.85 (0.52-1.37) 0.50
0.18Medium SYNTAX score 10 (3.3) 21 (6.2) –2.99 (–6.18 to 0.20) 0.52 (0.24-1.10) 0.08
Low SYNTAX score 13 (3.8) 9 (2.6) 1.21 (–1.37 to 3.79) 1.49 (0.64-3.50) 0.35
Cardiac death High SYNTAX score 8 (2.4) 17 (5.2) –2.78 (–5.62 to 0.06) 0.45 (0.19-1.04) 0.06
0.04Medium SYNTAX score 5 (1.7) 4 (1.2) 0.41 (–1.38 to 2.19) 1.41 (0.38-5.23) 0.61
Low SYNTAX score 5 (1.5) 1 (0.3) 1.16 (–0.21 to 2.53) 5.17 (0.60-44.50) 0.09
Target vessel 
MI (any)
High SYNTAX score 13 (3.8) 12 (3.7) 0.16 (–2.66 to 2.99) 1.04 (0.47-2.28) 0.93
0.53Medium SYNTAX score 5 (1.6) 11 (3.2) –1.64 (–3.96 to 0.68) 0.49 (0.17-1.42) 0.18
Low SYNTAX score 4 (1.2) 5 (1.4) –0.26 (–1.92 to 1.41) 0.82 (0.22-3.08) 0.77
Clinically 
indicated TLR
High SYNTAX score 19 (5.7) 9 (2.8) 2.80 (–0.17 to 5.76) 2.04 (0.92-4.51) 0.07
0.07Medium SYNTAX score 2 (0.7) 7 (2.1) –1.42 (–3.15 to 0.32) 0.32 (0.07-1.54) 0.13
Low SYNTAX score 4 (1.2) 5 (1.4) –0.26 (–1.92 to 1.41) 0.83 (0.22-3.09) 0.78
POCE*** High SYNTAX score 50 (14.6) 47 (14.2) 0.38 (–4.88 to 5.64) 1.03 (0.69-1.53) 0.90
0.56Medium SYNTAX score 22 (7.2) 29 (8.5) –1.54 (–5.61 to 2.53) 0.83 (0.48-1.45) 0.51
Low SYNTAX score 26 (7.7) 21 (6.0) 1.58 (–2.12 to 5.28) 1.29 (0.72-2.29) 0.39
Definite stent 
thrombosis
High SYNTAX score 4 (1.2) 3 (0.9) 0.26 (–1.26 to 1.77) 1.28 (0.29-5.74) 0.74
0.93Medium SYNTAX score 1 (0.3) 1 (0.3) 0.02 (–0.82 to 0.86) 1.11 (0.07-17.36) 0.94
Low SYNTAX score 0 (0.0) 0 (0.0)
Definite or 
probable stent 
thrombosis
High SYNTAX score 11 (3.2) 16 (4.8) –1.61 (–4.55 to 1.33) 0.66 (0.30-1.42) 0.28
0.67Medium SYNTAX score 5 (1.6) 11 (3.2) –1.64 (–3.96 to 0.68) 0.49 (0.17-1.42) 0.18
Low SYNTAX score 5 (1.5) 5 (1.4) 0.03 (–1.72 to 1.79) 1.03 (0.30-3.57) 0.96
Number of first events and percentages are reported. Rate ratios (RR [95% CI]) are estimated using the Mantel-Cox method with two-sided p-values 
from log-rank test. All events were censored beyond 365 days. Continuity corrected RR with Fisher’s exact test for zero outcomes. **Primary endpoint, 
defined as the composite of cardiac death, target vessel Q-wave or non-Q-wave MI, clinically indicated TLR. ***Patient-oriented composite endpoint 
which is death, MI, or any repeat revascularisation. ¶Approximate chi-square test for unequal RRs testing for effect modification of the difference 
between the stents due to the tertile groups. Approximate Z-test in case of zero events. High SYNTAX: >15; Medium SYNTAX: 8-15; Low SYNTAX: <8. 
MI: myocardial infarction; TLR: target lesion revascularisation
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Figure 4. Performance of the logistic clinical SS. A) Area under the curve and discrimination measures. B) Calibration plots. The triangles 
indicate the observed frequencies by quintile of predicted probabilities.
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Similarly, major cardiac event-free survival was lower for patients 
in the LEADERS trial in the highest tertile of SS2. The present 
study confirms the prognostic value of the SS by documenting 
higher mortality and higher risk of adverse events among patients 
with SS >15. The validation of such a predictive role in a real-
world population mirroring the currently increasing gradient of 
complexity for lesions and patients receiving DES supports the 
utility of implementing its use in current clinical practice.
To date, this study is among the first to assess the role of the 
SS in a large population treated with biodegradable polymer 
stents. While a sub-analysis of the LEADERS trial investigated 
clinical outcomes according to SS tertiles in patients treated with 
thick strut stainless steel biodegradable polymer DES2,12, we ana-
lysed patients treated with ultrathin strut cobalt-chromium bio-
degradable polymer DES in comparison with the best in class 
DP-EES.
In a recent pooled analysis of more than 6,000 patients from 
four all-comers trials (including the BIOSCIENCE trial), new-
generation DES were associated with improved clinical outcomes 
compared with early-generation DES across the entire spectrum 
of coronary disease complexity13. Our study further expands this 
observation by showing comparable performance of two new-gen-
eration DES, irrespective of the extent and severity of coronary 
disease.
Nevertheless, differences in the occurrence of the individ-
ual components of the primary endpoint have been detected 
within medium and high SS tertiles. We acknowledge that this 
subgroup analysis is underpowered and the observed results 
could be a play of chance, requiring a cautious interpretation. 
Indeed, the higher rates of target vessel MI and ST in patients 
with medium SS receiving DP-EES were not accompanied by 
a significantly increased rate of cardiac death. Moreover, there is 
no obvious explanation for higher rates of cardiac death among 
patients in the high SS tertile receiving DP-EES. A similar vari-
ability in the ability of SS to predict individual major outcomes 
has previously been pointed out3,12. It could be a consequence of 
the fact that the score includes several angiographic variables 
differentially affecting specific clinical endpoints. For example, 
the lesion length can be related to the occurrence of TVR whilst 
the disease of proximal vessels could be associated with sud-
den cardiac death14. On the other hand, it could be speculated 
that the peculiar features of the devices are responsible for the 
diverging outcomes. In this regard, the Orsiro stent represents 
the latest iteration of stent technology, featuring an ultrathin 
strut design with a biodegradable polymer aiming to overcome 
the safety issues of second-generation DES. Its safety and effi-
cacy profile was reassuringly preserved in high-risk groups such 
as diabetic patients15. Moreover, a beneficial effect of BP-SES 
over DP-EES has been advocated in patients presenting with 
STEMI16. However, the limited numbers of patients included in 
the previous and current analyses prevent us from establishing 
definitely the effect of the refined stent design and biodegradable 
polymer on prognosis.
Although this study was mainly focused on the performance of 
BP-SES and DP-EES across the spectrum of coronary anatomy 
complexity, we additionally assessed the ability of the logistic 
clinical SS to predict two-year mortality after PCI. To the best of 
our knowledge, this analysis represents the first external validation 
of this score. We found a good performance in terms of discrimi-
nation and calibration. Notably, the Harrell’s C-statistic observed 
in our study (0.73) perfectly matched with the c-index in the deri-
vation cohort (0.73), further corroborating the clinical utility of the 
logistic clinical SS.
Limitations
The present analysis has several limitations. First, the sub-analy-
sis was not pre-specified, and numbers are modest, compromis-
ing particularly the robustness of individual endpoint analyses. 
Second, the SS was evaluated retrospectively. However, assessors 
were blinded to the treatment arm and clinical outcomes, and inter- 
and intra-rater variability of calculated SS was low. Third, adher-
ence to dual antiplatelet therapy was high in the present cohort and 
may have further obliterated potential differences across groups.
Conclusions
Increasing lesion complexity as assessed by SS was associated 
with higher rates of TLF and POCE in a contemporary PCI popu-
lation. BP-SES and DP-EES performed similarly across the entire 
spectrum of CAD severity in terms of composite endpoints up to 
two years of follow-up. The observed differences in the occur-
rence of individual outcomes and the potential of the SS to dis-
criminate stent performance are only hypothesis-generating and 
deserve further evaluation. The external validation of the logistic 
clinical SS confirmed the utility of combining clinical and ana-
tomic variables for predicting long-term mortality after PCI.
Impact on daily practice
Our findings support the use of the SS as a valuable tool to 
predict the risk of adverse ischaemic events after PCI even in 
a contemporary scenario in which the complexity of patients 
receiving coronary stenting is rising apace. In addition, by con-
firming a comparable safety and efficacy profile as compared 
with the best performing durable polymer DES across the SS 
tertiles, they provide further insights concerning our knowledge 
of the newer-generation biodegradable polymer DES.
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Appendix. Methods
SYNTAX SCORE CALCULATION
Angiographic analyses were performed by two independent 
invasive cardiologists (M. Tanawaki, F. Rigamonti) at the Core 
Angiographic Laboratory of the Department of Cardiology of 
Bern University Hospital, Bern, Switzerland.
The operators were trained for score calculation and blinded 
to randomisation and clinical data. They scored each coronary 
lesion with a diameter stenosis ≥50% from the baseline angiogram 
according to the instructions available at the SS algorithm website 
(www.syntaxscore.com). The SS of 30 randomly selected cases 
were reassessed by the same readers four weeks later, with evi-
dence of high similarity between score ratings within a patient, and 
high reliability of individual patient ratings of the SS: intraclass 
correlation coefficients (ICC)=0.90 (95% CI: 0.80-0.95). Cases 
of disagreement were referred to the judgement of a third analyst 
and the final decision was reached by consensus. For patients with 
prior coronary artery bypass surgery (CABG), the CABG SS was 
applied. In-stent restenosis lesions were scored as de novo lesions.
LOGISTIC CLINICAL SYNTAX SCORE
Logistic clinical SS was calculated according to the extended 
model proposed by Iqbal et al7. The anatomic SS was combined 
with the following clinical variables: age (years), creatinine clear-
ance (ml/min), left ventricular ejection fraction (%), SYNTAX-
like patients (as fulfilling the enrolment criteria for the SYNTAX 
trial, i.e., left main stem or three-vessel disease), body mass index, 
diabetes mellitus, peripheral vascular disease.
STATISTICAL ANALYSIS
All patients with available SS were included in the analyses. 
Baseline characteristics and clinical outcomes were stratified 
according to SS tertile (low <8, medium 8-15, high >15) and study 
arm (BP-SES or DP-EES). Continuous variables were expressed 
as mean±standard deviation (SD); categorical variables were sum-
marised as frequencies (%). Cox regressions were used to com-
pare the outcomes between stent types across SS tertiles. In case of 
zero events in one comparator group, we reported continuity-cor-
rected risk ratios with p-values from Fisher’s exact tests. Survival 
curves up to two-year follow-up were constructed for time-to-event 
variables with Kaplan-Meier estimates and compared by the log-
rank test. We assessed performance of the logistic clinical SS using 
measures of calibration and discrimination. The calibration (how 
well the predicted event rate agrees with the observed event rate 
over a range of scores) was graphically assessed with plots of pre-
dicted vs. observed mortality rates by quintiles of logistic clini-
cal SS. The discrimination of the logistic clinical SS was assessed 
with the Harrell’s C-index for survival data, which measures the 
ability to distinguish patients who experience an adverse event 
from those who do not. Larger values indicate better discrimina-
tion. A p-value of <0.05 was considered significant, and all tests 
were two-tailed. All analyses were carried out with Stata Statistical 
Software: Release 13 (StataCorp LP., College Station, TX, USA).
